Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
doi: 10.1503/cmaj.101281 Summary Keywords sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, type 2 diabetes, metformin, meta-analysis Citation Deng R, Mei K, Song T, Huang J, Wu Y, Yu P, Yan Z and Liu X (2024) First-line treatment with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in type 2 diabetic population at low risk of cardiovascular disease: a meta-analysis
Lower energy expenditure: Resting metabolic rate decreases with weight loss as the body adapts and both lean and fat mass are reduced
1 FDA identified three core failures, with the first being Novo Nordisk's internal procedures allowing adverse events to be rejected or cancelled if the person reporting them believed the event was unrelated to the drug
The Future of Functional Medicine: FM 2.0 and Beyond Functional Medicine 2.0 (FM 2.0) represents the evolution of our field the bridge between root-cause discovery (FM 1.0) and systems precision repair (FM 2.0)
, GLP-1 ,
